logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

ALK+ NSCLC: brigatinib continues to outperform crizotinib

Second interim analysis of ALTA-1L trial finds better PFS, ORR with brigatinib.